| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC3045 |
| Trial ID | NCT05393804 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Abecma|bb2121|BMS-986395|Idecabtagene vicleucel|ide-cel |
| Location approved | US, Canada, EU, UK, Japan, Israel, Switzerland |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant |
| Year | 2022 |
| Country | United States |
| Company sponsor | Memorial Sloan Kettering Cancer Center |
| Other ID(s) | 22-118 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||||
|
|||||||||||||